title: The clinical significance of serum CD8 antigen levels in adult patients with Hodgkin's disease.
abstract: Increased suppressor T-cell activity has been observed in patients with Hodgkin's disease. In order to evaluate the clinical significance of soluble CD8 antigen (sCD8), which is released from CD8+ suppressor/cytotoxic T-lymphocytes, we determined sCD8 levels in the sera of 82 consecutive patients with newly diagnosed untreated Hodgkin's lymphoma who were entered into prospective trials of the German Hodgkin's Disease Study Group. sCD8 levels were significantly higher (p less than 0.01) in stage IV (781 U/ml, n = 19) than in stages I-IIIB (443 U/ml; n = 63). Patients with B-symptoms (n = 36) had slightly higher levels (611 U/ml) than patients without (n = 46) systemic symptoms (447 U/ml; p = 0.08). In 77 patients evaluable for response, the complete remission (CR) rate of patients with sCD8 less than 750 U/ml was higher (54/60 or 90%) than that of patients with sCD8 greater than 750 U/ml 11/17 or 65%; p = 0.01). The time to treatment failure was significantly longer in patients with sCD8 less than 750 U/ml (p = 0.008), even among the group with stages IIIB/IV only (p = 0.04). Our data suggest that the pretreatment levels of sCD8 in adult patients with Hodgkin's lymphoma have prognostic relevance, and that they should be determined especially in patients with advanced disease. Increased understanding of the role of sCD8 may shed light on the pathogenesis of Hodgkin's disease.
authors.affiliation: Medizinische Klinik I, University of Saarland, Fed. Rep. Germany.
authors.forename: A
authors.initials: A
authors.lastname: Gause
authors.forename: K
authors.initials: K
authors.lastname: Verpoort
authors.forename: V
authors.initials: V
authors.lastname: Roschansky
authors.forename: A
authors.initials: A
authors.lastname: Tschiersch
authors.forename: D
authors.initials: D
authors.lastname: Hasenclever
authors.forename: R
authors.initials: R
authors.lastname: Schmits
authors.forename: V
authors.initials: V
authors.lastname: Diehl
authors.forename: O
authors.initials: O
authors.lastname: Brosteanu
authors.forename: M
authors.initials: M
authors.lastname: Pfreundschuh
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D016827:CD8 Antigens / Q000032:analysis*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000276:immunology* / Q000628:therapy; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D014747:Vinblastine; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D016827:CD8 Antigens; D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone